You are here

Clinical Trials

Company plans FDA submission by mid-year
Analyst gives treatment 50/50 chance of coming to market
After 56 weeks of treatment with Saxenda, 91.7% of early responders maintained or lost additional weight
Drug demonstrated clinically meaningful results with infrequent subcutaneous administration
Treatment reduces mortality risk in patients with advanced disease
Results may put U.S. bladder cancer approval in doubt
Primary endpoints missed in lung and breast cancer studies
Bypassing agent reduces bleeds during 12 weeks of treatment
Roche to seek approval for first-line treatment
Study shows risk of device thrombosis
Treatment noninferior to piperacillin/tazobactam
Experts skeptical of $21,000-per-month treatment